Indication

Familial Platelet Disorder With Predisposition to Myeloid Malignancies

1 clinical trial

1 drug

Clinical trial

Phase Ib Study of Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Status: Recruiting, Estimated PCD: 2026-10-30

Drug